{
    "id": "8c148cfe-7719-4504-8628-0ae178fe4720",
    "indications": "jynarque indicated slow kidney function decline adults risk rapidly progressing autosomal dominant polycystic kidney disease ( adpkd ) .",
    "contraindications": "recommended ( 2.1 ) initial titration step target 1st dose 45 mg 1st dose 60 mg 1st dose 90 mg 2nd dose ( 8 hours later ) 15 mg 2nd dose ( 8 hours later ) 30 mg 2nd dose ( 8 hours later ) 30 mg total daily dose 60 mg total daily dose 90 mg total daily dose 120 mg dose adjustment recommended patients taking moderate cyp3a inhibitors ( 2.4 , 5.4 , 7.1 )",
    "adverseReactions": "jynarque contraindicated patients : history , signs symptoms significant liver impairment injury . contraindication apply uncomplicated polycystic liver disease [ ( 5.1 ) ] taking strong cyp3a inhibitors uncorrected abnormal blood sodium concentrations [ ( 5.3 ) ] unable sense respond thirst [ ( 5.3 ) ] hypovolemia [ ( 5.3 ) ] hypersensitivity ( e.g . , anaphylaxis , rash ) tolvaptan component product [ ( 6 ) ] uncorrected urinary outflow obstruction anuria",
    "ingredients": [
        {
            "name": "TOLVAPTAN",
            "code": "21G72T1950"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "2165RE0K14"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "FD&C BLUE NO. 2 ALUMINUM LAKE",
            "code": "4AQJ3LG584"
        }
    ],
    "organization": "Otsuka America Pharmaceutical, Inc.",
    "name": [
        {
            "name": "Jynarque"
        },
        {
            "name": "JYNARQUE"
        }
    ],
    "effectiveTime": "20250502",
    "indications_original": "JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).",
    "contraindications_original": "Recommended dosage ( 2.1 ) Initial Dosage Titration Step Target Dosage 1st Dose 45 mg 1st Dose 60 mg 1st Dose 90 mg 2nd Dose (8 hours later) 15 mg 2nd Dose (8 hours later) 30 mg 2nd Dose (8 hours later) 30 mg Total Daily Dose 60 mg Total Daily Dose 90 mg Total Daily Dose 120 mg Dose adjustment is recommended for patients taking moderate CYP3A inhibitors ( 2.4 , 5.4 , 7.1 )",
    "adverseReactions_original": "JYNARQUE is contraindicated in patients:\n                  \n                     With a history, signs or symptoms of significant liver impairment or injury. This contraindication does not apply to uncomplicated polycystic liver disease [see Warnings and Precautions (5.1)]\n                     \n                     Taking strong CYP3A inhibitors\n                     With uncorrected abnormal blood sodium concentrations [see Warnings and Precautions (5.3)]\n                     \n                     Unable to sense or respond to thirst [see Warnings and Precautions (5.3)]\n                     \n                     Hypovolemia [see Warnings and Precautions (5.3)]\n                     \n                     Hypersensitivity (e.g., anaphylaxis, rash) to tolvaptan or any component of the product [see Adverse Reactions (6)]\n                     \n                     Uncorrected urinary outflow obstruction\n                     Anuria"
}